

## FILE COPY

Receipt

PATENT 600-1-257 CIP

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:

JAMES A. BIBB AND PAUL GREENGARD

SERIAL NO. :

09/687,959

**EXAMINER**:

UNKNOWN

AN Z 3 2002

FILED

OCTOBER 13, 2000

ART UNIT

1614

FOR

METHODS OF IDENTIFYING AGENTS THAT REGULATE

PHOSPHORYLATION/DEPHOSPHORYLATION IN DOPAMINE

SIGNALING

#### Certificate of Mailing Under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231 on <u>June 5, 2001</u>.

Michael D. Davis, Reg. No. 39,161 (Name of Registered Rep.)

(Signature and Date)

#### REQUEST FOR CORRECTED OFFICIAL FILING RECEIPT

ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

Sir:

Enclosed is a copy of the Official Filing Receipt marked in red to show the correction that is needed. The correction is as follows.

Please change the total claims from "16" to read

- - 21- -

as it appears on the pages of claims filed on October 13, 2000. A copy of said pages of claims is enclosed.

Issuance of a corrected Official Filing Receipt is respectfully requested.

Respectfully submitted,

MICHAEL D. DAVIS

Attorney for Applicant(s)

Registration No. 39,161

KLAUBER & JACKSON 411 Hackensack Avenue Hackensack, New Jersey 07601 (201) 487-5800

Date: June 5, 2001

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.usoto.go/

 APPLICATION NUMBER
 FILING DATE
 GRP ART UNIT
 FIL FEE REC'D
 ATTY DOCKET NO
 DRAWINGS
 TOT CLAIMS
 IND CLAIMS

 09/687,959
 10/13/2000
 1614
 509
 600-1-257 CIP
 12
 16
 5

23565 KLAUBER & JACKSON 411 HACKENSACK AVENUE HACKENSACK, NJ 07601 **FILING RECEIPT** 

\*OC00000005895553\*

00000005895553"

Date Mailed: 03/23/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the chang s noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate):

Applicant(s)

RECEIVED

**TECH CENTER 1630/2900** 

James A. Bibb, New York, NY;
Paul Greengard, New York, NY;

JAN 2 3 2002

Continuing Data as Claimed by Applicant

THIS APPLICATION IS A CIP OF 09/419,379 10/15/1999 ABN

Foreign Applications

If Required, Foreign Filing License Granted 01/16/2001

\*\* SMALL ENTITY \*\*

Title

Methods of identifying agents that regulate phosphorylation/dephosphorylation in dopamine signaling

RECEIVEN

**Preliminary Class** 

APR 0.5 2001

514

11. 110ER & JASKSOII--

Data entry by : GENTRY, CHRISTINE

Team: OIPE

Date: 03/23/2001



### LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

#### **GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CRF 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

#### **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

#### PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents Office of Initial Patent Examination **Customer Service Center** Washington, DC 20231

# FILE COPY UNITED STATES PATENT AND TRADEMARK OFFICE



COMMISSIONER FOR PATENTS United States Patent and Trademark Office Washington, D.C. 20231 www.uspto.gov



Bib Data Sheet

**CONFIRMATION NO. 8464** 

SERIAL NUMBER 09/687,959	FILING DATE 10/13/2000 RULE	CLASS 800		ROUP ART UNIT 1632		ATTORNEY OCKET NO. 00-1-257 CIP	
	b, New York, NY; ard, New York, NY;						
THIS APPLIC	ATA ***********************************	19,379 10/15/1999 A	BN				
	CATIONS ************************************		ENTITY **				
Foreign Priority claimed 35 USC 119 (a-d) conditio met Verified and Acknowledged	STATE OF COUNTRY			IMS	INDEPENDENT CLAIMS 5		
ADDRESS 23565							
<b>TITLE</b> Methods of identifyi	ng agents that regulate pl	hosphorylation/depho	sphorylation	n dopamin	e sign	aling	
	FEES: Authority has been given in Paper No to charge/credit DEPOSIT ACCOUNT No for following:			☐ All Fees			
				1.16 Fees (Filing)			
FILING FEE FE				1.17 Fees ( Processing Ext. of time )			
509 No				☐ 1.18 Fees (Issue)			
				Other			
				☐ Credit			